CalciMedica, Inc.

Equities

CALC

US38942Q2021

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets 03:30:00 31/05/2024 am IST			5-day change	1st Jan Change
5.68 ^USD	+0.18%		+9.23%	+98.60%

13/05	CalciMedica, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
24/04	Calcimedica Inc. Announces Last Patient Enrolled in Phase 2B Carpo Trial of Auxora? in Acute Pancreatitis	CI

GrayBug, LLC Appoints Michael O'Rourke as President, CEO and Board Member

October 28, 2013 at 09:02 pm IST

GrayBug, LLC has announced the appointment of Michael O'Rourke as President & CEO, as well as Board Member. Michael O'Rourke brings more than eighteen years of global ophthalmic leadership, strategy and commercialization experience. Mr. O'Rourke is the Founder of Scotia Vision Consultants and was previously a member of the GrayBug scientific advisory board.

Latest news about CalciMedica, Inc.

CalciMedica, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
Calcimedica Inc. Announces Last Patient Enrolled in Phase 2B Carpo Trial of Auxora? in Acute Pancreatitis	24/04	CI
Top Premarket Decliners	01/04	MT
CalciMedica, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
CalciMedica Inc. Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International Acute Kidney Injury At the 29th International Aki & CRRT Conference	13/03	CI
JonesTrading Initiates CalciMedica With Buy Rating, Price Target is $22	16/02	MT
CalciMedica Gets FDA Nod for Phase 2 Trial of Acute Kidney Injury With Respiratory Failure Treatment	14/02	MT
Calcimedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora? for the Treatment of Severe Acute Kidney Injury	13/02	CI
CalciMedica, Inc. announced that it has received $20.252897 million in funding	05/02	CI
HC Wainwright Starts Coverage on CalciMedica with Buy Rating, $20 Price Target	29/01	MT
Calcimedica Insider Bought Shares Worth $2,515,080, According to a Recent SEC Filing	26/01	MT
CalciMedica Secures $55 Million Funding Deal With Investors; Shares Gain	22/01	MT
CalciMedica, Inc. announced that it expects to receive $20.4 million in funding	19/01	CI
CalciMedica, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
Top Premarket Decliners	07/11	MT
CalciMedica Inc. Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition	02/11	CI
CalciMedica, Inc.(NasdaqCM:CALC) added to S&P TMI Index	18/23/18	CI
CalciMedica Files $100 Million Mixed Shelf	14/23/14	MT
CalciMedica Inc. Announces First Patient Enrolled in International Expansion of CARPO Trial of Auxora in Acute Pancreatitis	09/23/09	CI
Top Premarket Gainers	27/23/27	MT
EF Hutton Initiates CalciMedica With Buy Rating, $17 Price Target	20/23/20	MT
CalciMedica, Inc.(NasdaqGM:CALC) dropped from S&P TMI Index	03/23/03	CI
CalciMedica, Inc.(NasdaqGM:CALC) dropped from NASDAQ Composite Index	29/23/29	CI
CalciMedicaAnnounces Executive Changes	23/23/23	CI
CalciMedica, Inc.(NasdaqGM:CALC) added to NASDAQ Composite Index	22/23/22	CI

Chart CalciMedica, Inc.

Duration

Period

More charts

Company Profile

CalciMedica Inc. is a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous (IV) formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase 2b trial (called CARPO - NCT04681066) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase 1/2 asparaginase induced pancreatic toxicity (AIPT) study (called CRSPA - NCT04195347).

Sector

Biotechnology & Medical Research

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.68 USD

Average target price

18.67 USD

Spread / Average Target

+228.64%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CALCIMEDICA, INC.	+98.60%	61M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B

Bio Therapeutic Drugs